Shots:

• The P-II study involves assessing the efficacy- safety and PK of Iptacopan (LNP023) in patients with C3G (Cohort A) and patients who have undergone a kidney transplant and have C3G recurrence (Cohort B)- interim results presented at ASN 2020
• Result: @12wks.- reduction in proteinuria (49%) as measured by 24hrs. UPCR assessment; improvement in plasma C3 level; inhibit alternative complement pathway activity; stabilized renal function as assessed by eGFR
• Iptacopan (PO) is a first-in-class reversible inhibitor of factor B and has received EMA’s PRIME designation for iptacopan in C3G and EMA’s ODD in IgAN. The therapy is in development for multiple renal conditions including C3G- IgAN- aHUS- iMN as well as in PNH which is a hematological disease

 ­ Ref: Novartis | Image: Novartis